Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.

Cheng F, Su L, Qian C. · 2016

Read Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer. by Cheng F, Su L, Qian C. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5217053.txt.

Description

Feifei Cheng, Li Su, and Cheng Qian reviewed circulating tumor DNA in Oncotarget in 2016. Tumours shed fragments of their DNA into the blood, and those fragments carry the same mutations as the tumour itself. Reading them, an approach called liquid biopsy, could avoid some limits of tissue biopsy, which struggles with early tumours and with cancers that change over time.

Studies so far find mutation screening in blood DNA to be highly sensitive and specific, raising hopes for earlier detection. The same tests can track how a tumour grows or shrinks, hint at outlook, and help match patients to targeted drugs. The review covers the biology of these fragments, the methods used to detect them, and their possible roles in diagnosis, treatment choice, and prognosis. The authors frame blood-based testing as a possible shift in how cancer is managed.

Catalog record

CREATORCheng F, Su L, Qian C.
YEAR2016
COLLECTIONPAPERS
FORMATTXT
FILE SIZE48 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5217053

Browse the full library · About the Tower of Babel